Shaw, S.M., Chaggar, P., Ritchie, J., Shah, M.K., Baynes, A.C., O’Neill, N., et al. (2009) The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin. Transplantation, 87, 771-775.
http://dx.doi.org/10.1097/TP.0b013e318198d7d0

has been cited by the following article:

• TITLE: Evaluation of the Management of Hyperlipidemia and Hypertension in an Outpatient Cardiac Transplant Clinic

  AUTHORS: Jane J. Xu, Ilene Burton, Wayne J. Tymchak, Glen J. Pearson

  KEYWORDS: Cardiac Transplant, Allograft Coronary Artery Disease, Graft Vaculopathy, Dyslipidemia, Hypertension

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.7 No.1, January 27, 2016

  ABSTRACT: Background: Allograft coronary artery disease (ACAD) is a common cause of morbidity and mortality post-orthotopic heart transplantation (OHT). ACAD progression may be reduced by modifying cardiovascular risk factors, such as hyperlipidemia and hypertension. We sought to evaluate the management of hyperlipidemia and hypertension among OHT recipients followed in an outpatient cardiac transplant clinic. Objective: The primary objective was to assess the proportion of OHT patients achieving both the recommended LDL target of